secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2022-11-16T23:59:59+00:00
Accession:  0001104659-22-119533
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion appoints Ben Halladay as CFO, effective Nov 16, 2022
-------------------------------------------------------------

- Ben Halladay appointed CFO effective Nov 16, 2022; previously Senior Director of FP&A at Esperion.
- Annual base salary of $429,000; target annual bonus of 40% of base salary.
- Reports to CEO Sheldon Koenig; prior roles at National Oilwell Varco, BMC Software, and Pfizer.
- Holds CPA license; BA from Syracuse University and MBA from Fordham Gabelli School of Business.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000110465922119533/0001104659-22-119533-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000110465922119533/tm2230242d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-119533

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer